DBCO-PEG4-Val-Cit-PAB-MMAE (CAS: 2129164-91-4)
DBCO-PEG4-Val-Cit-PAB-MMAE is a cutting-edge reagent designed for developing antibody-drug conjugates (ADCs) and targeted cancer therapies. This powerful compound combines efficient bioorthogonal click chemistry with a cleavable linker for precise drug delivery to cancer cells.
Key Features:
- DBCO Group: Promotes fast, click chemistry reactions for simple, catalyst-free conjugation to biomolecules.
- PEG4 Spacer: Improves solubility and flexibility, making it ideal for research and therapeutic use.
- Val-Cit Linker: Cleaves selectively within cancer cells, ensuring controlled release of the drug.
- PAB Linker: Triggers the release of MMAE, a cytotoxic agent that stops cell division, leading to cancer cell death.
Applications:
- Antibody-Drug Conjugates (ADCs): This compound is designed for precise drug delivery in cancer cells.
- Targeted Cancer Research: It offers a targeted approach to cancer therapy, reducing side effects and increasing treatment effectiveness.
Advantages:
- Highly Targeted: Focuses on cancer cells, reducing harm to healthy tissues.
- Versatile: Works with different cancer types, including blood cancers and solid tumors.
- Improved Solubility: The PEG4 spacer enhances stability and performance.
Research Impact:
This compound is pushing forward the development of more effective and safer cancer treatments. Its precision, combined with the potent effects of MMAE, is proving to be a game-changer in cancer therapy research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
